1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsInternational Research Collaboration on Cancer is sponsored by National Cancer Institute (NCI). Supports collaborative research projects between U. S.
and European researchers to advance cancer research.
Get alerted about grants like this
Save a search for “National Cancer Institute (NCI)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
International Cancer Research Partnership (ICRP) - NCI International Cancer Research Partnership (ICRP) The International Cancer Research Partnership (ICRP) is an alliance of cancer research funding organizations, including the Center for Global Health (CGH), that collaborate and strategically coordinate opportunities for cancer research across the globe.
ICRP helps define the landscape of global cancer research and identify opportunities for stronger collaboration.
It does this by: partnering with 173 government, public, and nonprofit international funding organizations that represent over $80 billion in investments for cancer research since 2000 managing a public database of information about funded cancer research projects, so users can find projects and collaborators and avoid duplicate efforts assessing trends in cancer research over time using the database hosting annual meetings and monthly webinars for cancer research funding organizations to share information and explore partnerships International Portfolio At a Glance CGH tracks and analyzes NCI-supported research with international collaborators.
These data help us recognize priorities, identify gaps, and foster collaborations between NCI, US-based institutions, and international institutions. CGH has a primary focus on increasing cancer research and capacity-building in low- and middle-income countries (LMICs), therefore, the involvement of researchers based at institutions in LMICs is often highlighted in the data below.
This portfolio includes both direct awards to international institutions and domestic awards with international collaborators. Domestic awards with international collaborators make up the majority (>95%) of NCI’s international extramural grants. This portfolio also includes collaborators in countries of all income classes and world regions.
Income classes and regions are defined by the World Bank , and NCI’s collaborations with LMICs is inclusive of countries categorized as low income, lower-middle income, and upper-middle income. The data presented here are sourced from the National Institutes of Health (NIH) and shared with our partners at ICRP.
Click on the source in images below to reach the ICRP database and search for cancer research funded by NIH or other ICRP partners. International Collaborations (Grants) by Region CGH’s core value of collaboration reflects an awareness of the enormity of global cancer as a public health problem, beyond the capacity of CGH or NCI to address alone.
Collaborative global research is key to achieving progress, and NCI funds global cancer research with principal investigators and collaborators in all eight world regions. Credit: National Cancer Institute Displays cancer grants active in FY 2023 funded by NIH Source: https://www. icrpartnership.
org/db_search? sid=62516 International Collaborations (Grants) by Cancer Continuum Focus Area NIH funds global cancer research across the cancer continuum, as represented by the Common Scientific Outline codes . Out of six scientific focus areas, 29% of grants are coded to treatment and 27% are coded to biology.
This aligns with CGH’s strategic research theme of increasing the understanding of cancer etiology and biology through collaborations with global investigators and populations. Prevention research is currently the lowest funded category, accounting for just 7% of grants. Grants can be coded to multiple focus areas.
Credit: National Cancer Institute Displays cancer grants active in FY 2023 funded by NIH Source: https://www. icrpartnership. org/db_search?
sid=62516 International Collaborations (Grants) by Cancer Site Cancer is not a single disease, and different cancer types require different prevention, detection, treatment, and control strategies. NIH funds global cancer research across more than fifty cancer sites in the body, and over a quarter of grants are not site-specific, meaning they apply to all cancer sites.
The image below shows the ten most studied cancer sites in the NIH global cancer research portfolio. Credit: National Cancer Institute Displays cancer grants active in FY 2023 funded by NIH Source: https://www. icrpartnership.
org/db_search? sid=62516 Global Cancer Research Training Grants CGH supports participation by international investigators in relevant NCI cancer research training curricula, co-funding for early career awards for global oncology researchers, and support for institutional research training collaborations between US institutions and international institutions.
CGH’s training support focuses on investigators based on low- and middle-income countries (LMICs) to enable equitable and impactful global scientific collaboration. Although research training makes up a small proportion of NIH’s global cancer research portfolio, it is a higher proportion of grants with collaborators in LMICs, especially in sub-Saharan Africa. In FY2023, 79% of research training grants included collaboration with LMICs.
Credit: National Cancer Institute Displays cancer grants active in FY 2023 funded by NIH Source: https://www. icrpartnership. org/db_search?
sid=62520 Clinical Trial Grants with International Collaborations CGH supports clinical trials with international collaborators and at international institutions as a key part of its research strategy. Given the critical importance of NCI-supported clinical trials in advancing progress against cancer, the limited NCI-supported clinical trials footprint in LMICs can likely be increased to realize important scientific opportunities.
NIH currently funds some clinical trials in LMICs by providing dedicated support for investigator-initiated clinical trials at NCI-Designated Cancer Centers with strong LMIC institution partnerships and by collaborating with other internal and external partners. In FY2023, 47% of clinical trial grants included collaboration with LMICs.
Credit: National Cancer Institute Displays cancer grants active in FY 2023 funded by NIH Source: https://www. icrpartnership. org/db_search?
sid=62522 Participation of Investigators in Global Cancer Research CGH supports innovative, impactful research in global cancer control through international collaboration. One of NCI’s strategic priorities is to increase the portfolio of NCI extramural funding involving collaborators in LMICs by developing new extramural funding initiatives and collaborating with other NCI extramural divisions and NIH ICOs.
Credit: National Cancer Institute Displays cancer grants funded by NIH Source: https://www. icrpartnership. org/db_search?
sid=62524 Organizations interested in becoming a partner are welcome to visit the ICRP website and follow the application guidelines . For information about ICRP, please contact Operations Manager, Lynne Davies . For more information about NCI's role in ICRP, please contact Ms. Elise Garton and Ms. Tosca Le .
Since 2000, ICRP partners have represented a wide range of governmental, public, and nonprofit cancer research funding organizations from across the world. See the full list of ICRP partners and funding organizations .
Based on current listing details, eligibility includes: Nonprofits, Universities, State/local governments, For-profit organizations, Small businesses, Individuals Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). This NOFO encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. It specifically mentions the integration of modeling and simulation approaches to guide rational nanomaterial design and the use of artificial intelligence (AI) and modeling to aid rational drug design. This directly relates to personalized medicine and cancer treatment, though the primary focus is nanotechnology.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
NIH NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) is a grant from the National Institutes of Health (NIH) / National Cancer Institute (NCI) that funds early-stage postdoctoral researchers in cancer-related fields to transition to independent research careers. The award provides a mentored phase (K99) followed by an independent phase (R00), supporting investigators who do not require an extended period of supervised training beyond their doctoral degrees. Eligible applicants must hold a research or clinical doctoral degree and be postdoctoral fellows who have not yet established independent research careers. The March 11, 2026 due date applies; award amounts vary by project.